文献速递糖尿病

前瞻性随机安慰剂对照试验评估银敷料促进急性糖尿病相关足溃疡愈合的疗效

Prospective randomised placebo-controlled trial assessing the efficacy of silver dressings to enhance healing of acute diabetes-related foot ulcers.
PubMed 文献 · Diabetologia · 2023-01-11

这项开放标签随机对照试验将无骨髓炎或肌腱外露、病程<6周的急性糖尿病相关足溃疡患者1:1分为Acticoat银敷料组与无银敷料对照组,均加标准治疗。12周溃疡愈合比例对照组75% vs 银组69%(p=0.49),调整后银敷料与愈合无关联(OR 0.92;CI 0.26, 3.22;p=0.53),愈合时间、骨髓炎、截肢及抗生素使用均无差异。

要点

  • 急性糖尿病相关足溃疡中,银敷料12周愈合比例对照组75% vs 银组69%,无差异(p=0.49)。
  • 调整周围动脉疾病、感染和初始溃疡大小后,银敷料与愈合无关联(OR 0.92;CI 0.26, 3.22;p=0.53)。
  • 愈合时间、进展为骨髓炎、截肢需求及抗生素使用或疗程均无差异。

核心结论

  • 在无骨髓炎或肌腱外露的急性糖尿病相关足溃疡患者中,与无银敷料相比,Acticoat银敷料未改善伤口愈合并未减少抗生素需求。

研究设计与样本

  • 开放标签随机对照试验;连续就诊于三级多学科糖尿病足服务的无骨髓炎或肌腱外露、病程<6周的糖尿病相关足溃疡患者,按1:1计算机生成随机化分为Acticoat(Smith & Nephew,英国)银敷料组或无银敷料对照组,均加标准治疗;分层随机化确保周围动脉疾病和感染在两组间均衡处理。
  • 对照组76处溃疡(55名参与者),银组91处溃疡(63名参与者);主要结局为12周时溃疡愈合比例。

主要发现

  • 12周溃疡愈合比例对照组75% vs 银组69%(p=0.49)。
  • 调整周围动脉疾病、感染和初始溃疡大小后,银敷料与愈合无关联(OR 0.92;CI 0.26, 3.22;p=0.53)。
  • 愈合时间、进展为骨髓炎、截肢需求、抗生素治疗需求或疗程均无差异。

关键数值与推荐

  • 主要结局为12周时溃疡愈合比例。
  • 次要结局包括愈合时间及溃疡缩小50%的时间、骨髓炎和截肢发生率、抗生素需求及疗程。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: Silver dressings are used for their antimicrobial properties but there is limited evidence of clinical benefit when managing diabetes-related foot ulcers (DFUs). We aimed to assess whether silver dressings in acute DFUs increased the proportion of ulcers healed compared with non-silver dressings. METHODS: In this open-labelled, randomised controlled trial, consecutive individuals who presented to a tertiary multidisciplinary diabetic foot service with a DFU without osteomyelitis or tendon on view of <6 weeks' duration were randomised 1:1 via a computer-generated randomisation process to receive Acticoat (Smith & Nephew, England) dressing (silver group) or dressing without silver (control group) in addition to standard care. Stratified randomisation was performed to ensure that the presence of peripheral arterial disease and infection were equally managed within the two groups. The primary outcome was the proportion of ulcers healed at 12 weeks. Secondary outcomes included time to heal and to 50% ulcer reduction, rates of osteomyelitis and amputation, and need for and duration of antibiotics. RESULTS: Seventy-six ulcers (55 participants) in the control group and 91 ulcers (63 participants) in the silver group were included. There was no difference in the proportion of ulcers healed by 12 weeks in the control vs silver group (75% vs 69%, p=0.49). After adjustment for presence of peripheral arterial disease, infection and initial ulcer size, silver dressing was not associated with odds of healing (OR 0.92; CI 0.26, 3.22; p=0.53). There was no difference in time to healing, progression to osteomyelitis, need for amputation, or duration of or need for antibiotic treatment. CONCLUSIONS/INTERPRETATION: In individuals with acute DFUs without osteomyelitis or tendon on view, Acticoat silver dressings did not improve wound healing or reduce need for antibiotics compared with non-silver dressings. TRIAL REGISTRATION: Australian New Zealand Clinical Trials Registry ACTRN12614001234606 FUNDING: Australian Diabetes Society-unrestricted research award.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Lafontaine N, Jolley J, Kyi M, et al. Prospective randomised placebo-controlled trial assessing the efficacy of silver dressings to enhance healing of acute diabetes-related foot ulcers. Diabetologia. 2023. PMID: 36629877. doi:10.1007/s00125-022-05855-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。